NVDA
NVIDIA
-- 142.620 TSLA
Tesla
-- 406.580 PLTR
Palantir
-- 78.980 AAPL
Apple
-- 222.780 MSTR
MicroStrategy
-- 353.670 
NEWS
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
1 hour ago, 5:00 AM PST
Via GlobeNewswire
ABOS
Share
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E
Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025
1 hour ago, 5:00 AM PST
Via GlobeNewswire
ABOS
Share
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E
Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
7060
Followers
46
Following
76K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day